Nami Hirano

1.0k total citations · 1 hit paper
15 papers, 644 citations indexed

About

Nami Hirano is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Nami Hirano has authored 15 papers receiving a total of 644 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 7 papers in Cancer Research and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Nami Hirano's work include Colorectal Cancer Treatments and Studies (10 papers), Cancer Genomics and Diagnostics (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Nami Hirano is often cited by papers focused on Colorectal Cancer Treatments and Studies (10 papers), Cancer Genomics and Diagnostics (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Nami Hirano collaborates with scholars based in Japan and United States. Nami Hirano's co-authors include Shogo Nomura, Akihiro Sato, Akihito Kawazoe, Hiroyoshi Nishikawa, Kohei Shitara, Hiroki Hara, Daisuke Kotani, Yuichi Mikamoto, Yosuke Togashi and Masashi Wakabayashi and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Frontiers in Oncology.

In The Last Decade

Nami Hirano

15 papers receiving 637 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)

2020 567 citations Shota Fukuoka, Hiroki Hara et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nami Hirano Japan	7	535	191	178	134	104	15	644
Hitomi Tamura Japan	6	553 1.0×	199 1.0×	188 1.1×	145 1.1×	109 1.0×	11	661
Takako Yoshii Japan	8	579 1.1×	284 1.5×	195 1.1×	218 1.6×	110 1.1×	37	773
Holly Kemberling United States	7	471 0.9×	154 0.8×	185 1.0×	125 0.9×	99 1.0×	9	567
Yuichi Mikamoto Japan	7	688 1.3×	318 1.7×	219 1.2×	196 1.5×	147 1.4×	10	852
Akiko Kawano Nagatsuma Japan	12	381 0.7×	387 2.0×	101 0.6×	153 1.1×	57 0.5×	16	653
Chuanhua Zhao China	12	278 0.5×	141 0.7×	93 0.5×	74 0.6×	60 0.6×	35	420
Irfan Firdaus United States	9	303 0.6×	185 1.0×	82 0.5×	84 0.6×	17 0.2×	15	479
Toshiro Ogura Japan	11	270 0.5×	162 0.8×	69 0.4×	108 0.8×	29 0.3×	45	554
Kimiyo Tabata Japan	7	365 0.7×	158 0.8×	166 0.9×	77 0.6×	149 1.4×	12	665
Aysel Ahadova Germany	13	401 0.7×	99 0.5×	420 2.4×	120 0.9×	53 0.5×	31	629

Countries citing papers authored by Nami Hirano

Since Specialization

Citations

This map shows the geographic impact of Nami Hirano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nami Hirano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nami Hirano more than expected).

Fields of papers citing papers by Nami Hirano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nami Hirano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nami Hirano. The network helps show where Nami Hirano may publish in the future.

Co-authorship network of co-authors of Nami Hirano

This figure shows the co-authorship network connecting the top 25 collaborators of Nami Hirano. A scholar is included among the top collaborators of Nami Hirano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nami Hirano. Nami Hirano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

1.

Hanai, Akiko, Sadamoto Zenda, Keita Mori, et al.. (2023). Mitigation of paclitaxel-induced peripheral neuropathy in breast cancer patients using limb-cooling apparatus: a study protocol for a randomized controlled trial. Frontiers in Oncology. 13. 1216813–1216813. 1 indexed citations

2.

Taniguchi, Hiroya, Taroh Satoh, Shigenori Kadowaki, et al.. (2023). Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA (cfDNA) testing: Results from a phase 2 basket trial (HERALD/EPOC1806).. Journal of Clinical Oncology. 41(16_suppl). 3014–3014. 19 indexed citations

3.

Masuishi, Toshiki, Hiroya Taniguchi, Daisuke Kotani, et al.. (2020). SO-25 A multicenter phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer: BRAVERY study (EPOC1701). Annals of Oncology. 31. S226–S226. 2 indexed citations

4.

Kawazoe, Akihito, Daisuke Takahari, Keisho Chìn, et al.. (2020). A multicenter phase II study of TAS-114 in combination with S-1 in patients with pretreated advanced gastric cancer (EPOC1604). Gastric Cancer. 24(1). 190–196. 9 indexed citations

5.

Shitara, Kohei, Hiroki Hara, Naoki Takahashi, et al.. (2020). Updated results from a phase Ib trial of regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer (REGONIVO, EPOC1603).. Journal of Clinical Oncology. 38(4_suppl). 135–135. 9 indexed citations

6.

Nakamura, Yoshiaki, Takayuki Yoshino, Yoshito Komatsu, et al.. (2020). A basket trial of trastuzumab deruxtecan, a HER2-targeted antibody-drug conjugate, for HER2-amplified solid tumors identified by circulating tumor DNA analysis (HERALD trial).. Journal of Clinical Oncology. 38(15_suppl). TPS3650–TPS3650. 7 indexed citations

7.

Hara, Hiroki, Akihito Kawazoe, Yasutoshi Kuboki, et al.. (2020). Scoop: Multicenter phase I/II trial of BBI608 and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503).. Journal of Clinical Oncology. 38(4_suppl). 107–107. 4 indexed citations

8.

Fukuoka, Shota, Hiroki Hara, Naoki Takahashi, et al.. (2020). Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). Journal of Clinical Oncology. 38(18). 2053–2061. 567 indexed citations breakdown →

9.

Masuishi, Toshiki, Hiroya Taniguchi, Daisuke Kotani, et al.. (2019). Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer. ESMO Open. 4(6). e000590–e000590. 2 indexed citations

10.

Takahari, Daisuke, Akihito Kawazoe, Yoshiaki Nakamura, et al.. (2019). A multicenter phase II study of TAS-114 in combination with S-1 in patients with pre-treated advanced gastric cancer (EPOC1604). Annals of Oncology. 30. v303–v304. 1 indexed citations

11.

Kojima, Takashi, Toshiyoshi Fujiwara, Yasuhiro Shirakawa, et al.. (2018). An open label phase I study to evaluate the safety and efficacy of OBP-301 with pembrolizumab in patients with advanced solid tumors.. Journal of Clinical Oncology. 36(15_suppl). TPS3117–TPS3117. 2 indexed citations

12.

Masuishi, Toshiki, Hiroya Taniguchi, Daisuke Kotani, et al.. (2018). BRAVERY study: A multicenter phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer (EPOC1701). Annals of Oncology. 29. viii202–viii202. 1 indexed citations

13.

Kawazoe, Akihito, Yasutoshi Kuboki, Yoshito Komatsu, et al.. (2018). Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.. Journal of Clinical Oncology. 36(15_suppl). 3530–3530. 10 indexed citations

14.

Kawazoe, Akihito, Yasutoshi Kuboki, Yoshito Komatsu, et al.. (2018). Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.. Journal of Clinical Oncology. 36(4_suppl). 760–760. 7 indexed citations

15.

Kuboki, Yasutoshi, Yoshito Komatsu, Miki Fukutani, et al.. (2017). Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.. Journal of Clinical Oncology. 35(15_suppl). TPS3623–TPS3623. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact